Spots Global Cancer Trial Database for arq 197
Every month we try and update this database with for arq 197 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | NCT01656265 | Advanced Hepato... | ARQ 197 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | NCT00612209 | Cancer, Advance... | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors | NCT01149720 | Solid Tumors | Tivantinib (ARQ... Tivantinib (ARQ... Tivantinib (ARQ... | 18 Years - | Daiichi Sankyo | |
| A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma | NCT00558207 | Pancreatic Neop... | ARQ 197 gemcitabine | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | NCT00612703 | Cancer | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | NCT00988741 | Unresectable He... | ARQ 197 Placebo | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922 | Solid Tumor | Pazopanib ARQ 197 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922 | Solid Tumor | Pazopanib ARQ 197 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT00777309 | Non Small Cell ... | ARQ 197 Erlotinib Placebo | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | NCT00612703 | Cancer | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | NCT01656265 | Advanced Hepato... | ARQ 197 | 20 Years - | Kyowa Kirin Co., Ltd. | |
| ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Phase 2 Study in Patients With MiT Tumors | NCT00557609 | Renal Cell Carc... Alveolar Soft P... Clear Cell Sarc... | ARQ 197 | 13 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pazopanib and ARQ 197 for Advanced Solid Tumors | NCT01468922 | Solid Tumor | Pazopanib ARQ 197 | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
